Results 201 to 210 of about 126,024 (329)

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial [PDF]

, 2014
Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, Lorenzo D’Ambrosio, Rossella Bertulli, Sebastian Dorin Asaftei, Angela Tamburini, Ymera Pignochino, Dario Sangiolo, Emanuela Marchesi, Federica Capozzi, R. Biagini, Marco Gambarotti, Franca Fagioli, Paolo G. Casali, Piero Picci, Stefano Ferrari, Massimo Aglietta   +17 more
openalex   +1 more source

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib

, 2020
Yen‐Yang Chen, Chih-Chi Wang, Yueh‐Wei Liu, Weifeng Li, Yen‐Hao Chen   +4 more
openalex   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Antiangiogenic activity of zinc and zinc-sorafenib combination using the chick chorioallantoic membrane assay: A descriptive study

, 2019
Manu Kumar Shetty, Girish Gulab Meshram, Tripti Rastogi, Sonal Sharma, Rachna Gupta, Seema Jain, Anisha Prasad, Vikas Galav, Sanjib Bhattacharya   +8 more
openalex   +1 more source

Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study

, 2021
Yashwant Patıdar, Karamvir Chandel, Naveen Kumar Condati, Shyam Srinivasan, Amar Mukund, Shiv K. Sarin   +5 more
openalex   +2 more sources

MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe

Cancer Science, Volume 117, Issue 2, Page 377-392, February 2026.
MASTL drives hepatocellular carcinoma (HCC) progression and paclitaxel resistance by triggering mitotic catastrophe. Depletion of MASTL induces DNA damage and promotes mitotic catastrophe, leading to cell death in HCC. MASTL‐mediated mitotic catastrophe depends on PP2A‐B55α activity, suggesting a novel therapeutic target for overcoming chemotherapy ...
Ke Wang, Ziwei Fu, Chuan Xiong, Jing Zhang, Qiang Luo   +4 more
wiley   +1 more source

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan

, 2019
Sadahisa Ogasawara, Yoshihiko Ooka, Norio Itokawa, Masanori Inoue, Shinichiro Okabe, Atsuyoshi Seki, Yuki Haga, Masamichi Obu, Masanori Atsukawa, Ei Itobayashi, Hideaki Mizumoto, Nobuyuki Sugiura, Ryosaku Azemoto, Kengo Kanayama, Hiroaki Kanzaki, Susumu Maruta, Takahiro Maeda, Yuko Kusakabe, Masayuki Yokoyama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato   +31 more
openalex   +1 more source

Tyrosinkinaseinhibition bei humanen Non-Hodgkin-Lymphomen: Präklinische Evaluation von Sorafenib [PDF]

, 2010
Nikolai Schuelper
openalex   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source